Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

MIRV clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 8 trials in our USA, Spain, Belgium, UK, France, Canada, Australia, Ireland, China, South Korea, Germany, Italy, Denmark, Switzerland, Czechia, Brazil, Japan, Taiwan, Poland, Mexico, India, Sweden, Israel, Netherlands, Austria, Norway and Singapore registers that name MIRV as an intervention. Synced 10 Nov 2026
8Current trials
5Recruiting now
5Lead sponsors
27Country registers
At a glance

MIRV is named as an intervention in 8 current clinical trials in our USA, Spain, Belgium, UK, France, Canada, Australia, Ireland, China, South Korea, Germany, Italy, Denmark, Switzerland, Czechia, Brazil, Japan, Taiwan, Poland, Mexico, India, Sweden, Israel, Netherlands, Austria, Norway and Singapore registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AbbVie (4). The most-studied condition is Primary Peritoneal Cancer.

Patient leaflets for MIRV

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting563%
  • Not yet open113%
  • Active, closed225%

Trials by phase

  • Phase 2563%
  • Phase 3225%
  • Phase 1113%
01

Clinical trials of MIRV

8 trials
StudyPhaseStatusLead sponsorRegisters
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Phase 3 Recruiting Eli Lilly and Company Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809 · Epithelial Ovarian Cancer
Phase 3 Recruiting AstraZeneca Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Switzerland, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988 · Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
Phase 2 Recruiting AbbVie UK, USA, France, Spain, Belgium, Poland, South Korea, Australia
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT06890338 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase 2 Recruiting AbbVie USA
A Study of PHST001 in Advanced Solid Tumors
NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer
Phase 1 Recruiting Pheast Therapeutics USA
Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
NCT07825753 · ClinicalTrials.gov ↗ · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
Phase 2 Not yet open Fudan University China
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685 · High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Phase 2 Active, closed AbbVie UK, USA, Spain, Belgium, Canada, Mexico
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853 · Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Phase 2 Active, closed AbbVie Ireland, USA, France, Spain, Belgium, Canada, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with MIRV

19 conditions
Primary Peritoneal Cancer3Epithelial Ovarian Cancer2Fallopian Tube Cancer2Ovarian Neoplasms1Fallopian Tube Neoplasms1Peritoneal Neoplasms1Neoplasm Metastasis1Recurrent Ovarian Cancer1Folate Receptor-Alpha Positive1High Grade Ovarian Cancer1Advanced High-Grade Epithelial Ovarian Cancer1Fallopian Tube Cancers1
All 19 conditions
Condition (as registered)Trials
Primary Peritoneal Cancer3
Epithelial Ovarian Cancer2
Fallopian Tube Cancer2
Ovarian Neoplasms1
Fallopian Tube Neoplasms1
Peritoneal Neoplasms1
Neoplasm Metastasis1
Recurrent Ovarian Cancer1
Folate Receptor-Alpha Positive1
High Grade Ovarian Cancer1
Advanced High-Grade Epithelial Ovarian Cancer1
Fallopian Tube Cancers1
Neoadjuvant1
Advanced Solid Tumors1
Ovarian Cancer1
Endometrial Cancer1
Cholangiocarcinoma1
Advanced or Metastatic Pancreatic Adenocarcinoma1
Advanced or Metastatic Breast Cancer (BC)1
05

Related compounds

06

Questions about MIRV trials

How many clinical trials are testing MIRV?

8 current trials in our USA, Spain, Belgium, UK, France, Canada, Australia, Ireland, China, South Korea, Germany, Italy, Denmark, Switzerland, Czechia, Brazil, Japan, Taiwan, Poland, Mexico, India, Sweden, Israel, Netherlands, Austria, Norway and Singapore registers name MIRV as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are MIRV trials recruiting patients?

Yes. 5 of the 8 trials are recruiting: 5 with sites in USA, 3 with sites in Spain, 3 with sites in Belgium, 3 with sites in UK, 3 with sites in France, 2 with sites in Canada, 3 with sites in Australia, 2 with sites in Ireland, 2 with sites in China, 3 with sites in South Korea, 2 with sites in Germany, 2 with sites in Italy, 2 with sites in Denmark, 2 with sites in Switzerland, 2 with sites in Czechia, 2 with sites in Brazil, 2 with sites in Japan, 2 with sites in Taiwan, 2 with sites in Poland, 1 with sites in Mexico, 1 with sites in India, 1 with sites in Sweden, 1 with sites in Israel, 1 with sites in Netherlands, 1 with sites in Austria, 1 with sites in Norway and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors MIRV clinical trials?

AbbVie (4), AstraZeneca (1), Eli Lilly and Company (1) and Pheast Therapeutics (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there MIRV clinical trials in Ireland?

Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MIRV works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MIRV works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MIRV (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.